The following is a summary of “Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy,” published in the January 2025 ...

Background Multiple system atrophy (MSA ... Quantitative brain imaging using 3T MRI was performed before and after treatment. Results Nine subjects were enrolled, and seven (2 women and 5 men, ...

Local estrogen therapy is the treatment of choice for women with vulvovaginal atrophy who lack other postmenopausal symptoms. Systemic estrogen therapy is indicated for vulvovaginal atrophy only ...

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

HYDERABAD: Health will become more personalised and accessible, with innovations across nutrition, paediatrics, dermatology, ...

A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

No significant differences with respect to type of treatment, duration of treatment and changes ... The main findings of the study are that the development of whole brain, cortical and putamen atrophy ...

Anti-trans conspiracies driven by right-wing activists and lawmakers broke up my family, but they can’t destroy me.